Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
Search
Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
More
Search
Home
Tags
Exon 51
Exon 51
Press Releases
PepGen Announces It Will Halt Clinical Trials of Exon 51 Skipping Study
Press Releases
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Research
Upcoming Exon 51 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
Research
Shanghai Jiao Tong University School of Medicine Begins Clinical Trials of LE051 Exon 51 Skipping Therapy
Press Releases
Eteplirsen (Exondys 51) Treatment Significantly Slows Heart Function Decline in Duchenne Muscular Dystrophy
Press Releases
Dyne Therapeutics Announces Unprecedented and Sustained Functional Improvement Through 18 Months from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy
Press Releases
PepGen Temporarily Pauses Exon 51 Skipping Study
Editorials
Turkish DMD Patients Who are Eligible for Exon 51 Skipping Treatment (Eteplirsen) Request Their Medications from the Ministry of Health
Popular
Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy
DMD Warrior
-
December 26, 2024
Must Read
Press Releases
Translarna (Ataluren) Rejected by EMA: Marketing Authorization Not Renewed
Editorials
DMD WarrioR’s Turkish Representative Shares His Views on Elevidys Gene Therapy: Is It Effective and Why Is It Expensive?
Research
Fn14 Protein May Protect Muscle Stem Cells, Offering Promise for Development of Duchenne Treatments